Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Oncolytics Biotech Inc

+ Add to Watchlist

ONC:CN

0.8800 CAD 0.0300 3.53%

As of 15:57:13 ET on 05/05/2015.

Snapshot for Oncolytics Biotech Inc (ONC)

Open: 0.8600 Day's Range: 0.8300 - 0.9000 Volume: 337,823
Previous Close: 0.8500 52wk Range: 0.4450 - 1.8000 1-Yr Rtn: -44.65%

Stock Chart for ONC

No chart data available.
  • ONC:CN 0.8700
  • 1D
  • 1M
  • 1Y
0.8500
Interactive ONC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ONC

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPTSX -
Earnings Per Share (CAD) (ttm) -0.2000
Est. EPS (CAD) (12/2015) -0.1840
Est. PEG Ratio -
Market Cap (M CAD) 96.54
Shares Outstanding (M) 109.71
30 Day Average Volume 368,907
Price/Book (mrq) 5.9548
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ONC

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for ONC

Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.

Bradley G Thompson "Brad"Chairman/President/CEOKirk LookChief Financial Officer
Matthew C Coffey "Matt"COO/Co-FounderAlan J TuchmanSenior VP:Clinical/Chief Medical Ofcr
More Company Profile & Key Executives for ONC

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil